ICU Medical (ICUI) to Release Earnings on Thursday

ICU Medical (NASDAQ:ICUI) is expected to be posting its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect ICU Medical to post earnings of $1.54 per share and revenue of $511.46 million for the quarter. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS.Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating the consensus estimate of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company had revenue of $543.57 million during the quarter, compared to analysts’ expectations of $543.33 million. During the same quarter in the previous year, the company posted $1.56 EPS. The business’s revenue for the quarter was down 8.0% compared to the same quarter last year. On average, analysts expect ICU Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical Stock Up 2.3%

NASDAQ:ICUI opened at $125.66 on Wednesday. ICU Medical has a 12-month low of $107.00 and a 12-month high of $196.26. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $3.10 billion, a P/E ratio of -82.67 and a beta of 0.83. The stock’s fifty day simple moving average is $123.81 and its 200-day simple moving average is $128.19.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Piper Sandler lifted their target price on ICU Medical from $145.00 to $153.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. KeyCorp dropped their price target on ICU Medical from $191.00 to $173.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 21st. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday, September 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Finally, Raymond James Financial cut their price target on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, ICU Medical presently has a consensus rating of “Moderate Buy” and a consensus target price of $176.50.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, Director David C. Greenberg acquired 1,200 shares of ICU Medical stock in a transaction dated Wednesday, August 27th. The stock was bought at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the purchase, the director directly owned 7,960 shares in the company, valued at approximately $1,006,303.20. This represents a 17.75% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Vivek Jain acquired 21,929 shares of the firm’s stock in a transaction dated Thursday, August 14th. The stock was bought at an average price of $112.84 per share, with a total value of $2,474,468.36. Following the acquisition, the chief executive officer directly owned 130,149 shares in the company, valued at $14,686,013.16. This represents a 20.26% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC raised its stake in shares of ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares in the last quarter. Headlands Technologies LLC acquired a new position in ICU Medical during the second quarter worth $177,000. United Services Automobile Association bought a new stake in ICU Medical during the first quarter worth $218,000. BNP Paribas Financial Markets grew its holdings in ICU Medical by 4.5% during the second quarter. BNP Paribas Financial Markets now owns 2,459 shares of the medical instruments supplier’s stock worth $325,000 after purchasing an additional 107 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in ICU Medical by 433.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,573 shares of the medical instruments supplier’s stock worth $340,000 after buying an additional 2,091 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.